PHARMEA

The PharMEA Platform: Multi-Electrode Array technology based platform for industrial pharmacology and toxicology drug screening

Coordinatore	AYANDA BIOSYSTEMS SA    more  Organization address address: "Parc Scientific EPFL, PSE" city: LAUSANNE postcode: 1015 contact info Titolo: Dr. Nome: Marc Cognome: Heuschkel Email: send email Telefono: +41 21 6938631 Fax: +41 21 6938631
Nazionalità Coordinatore	Switzerland [CH]
Totale costo	1˙885˙200 €
EC contributo	1˙452˙000 €
Programma	FP7-SME Specific Programme "Capacities": Research for the benefit of SMEs
Code Call	FP7-SME-2008-1
Funding Scheme	BSG-SME
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-09-01   -   2011-11-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	AYANDA BIOSYSTEMS SA  Organization address address: "Parc Scientific EPFL, PSE" city: LAUSANNE postcode: 1015 contact info Titolo: Dr. Nome: Marc Cognome: Heuschkel Email: send email Telefono: +41 21 6938631 Fax: +41 21 6938631	CH (LAUSANNE)	coordinator	517˙500.00
2	BIO-LOGIC  Organization address address: RUE DE L'EUROPE 1 city: CLAIX postcode: 38640 contact info Titolo: Mr. Nome: Thierry Cognome: Kauffmann Email: send email Telefono: +33 4 76986831 Fax: +33 4 76986909	FR (CLAIX)	participant	656˙400.00
3	CAPSANT NEUROTECHNOLOGIES LIMITED  Organization address address: VENTURE ROAD 2 city: SOUTHAMPTON postcode: SO16 7NP contact info Titolo: Prof. Nome: Lars Cognome: Sundstrom Email: send email Telefono: +44 1794 830205 Fax: +44 1794 516624	UK (SOUTHAMPTON)	participant	244˙500.00
4	HAUTE ECOLE SPECIALISEE DE SUISSE OCCIDENTALE  Organization address address: RUE DE LA JEUNESSE 1 city: DELEMONT postcode: 2800 contact info Titolo: Prof. Nome: Philippe Cognome: Passeraub Email: send email Telefono: +41 22 5462632 Fax: +41 22 5462575	CH (DELEMONT)	participant	16˙800.00
5	COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES  Organization address address: RUE LEBLANC 25 city: PARIS 15 postcode: 75015 contact info Titolo: Mr. Nome: Olivier Cognome: Hatem Email: send email Telefono: +33 4 38783057 Fax: +33 4 38785182	FR (PARIS 15)	participant	8˙400.00
6	Synome Ltd  Organization address address: MONETA BUILDING BABRAHAM RESEARCH CAMPUS city: Cambridge postcode: CB22 3AT contact info Titolo: Dr. Nome: Seth Cognome: Grant Email: send email Telefono: +44 1223 352200 Fax: +44 1223 281399	UK (Cambridge)	participant	8˙400.00
7	HAUTE ECOLE D'INGENIERIE ET DE GESTION DU CANTON DE VAUD  Organization address address: ROUTE DE CHESEAUX 1 city: YVERDON-LES-BAINS postcode: 1401 contact info Titolo: Prof. Nome: Andres Cognome: Perez-Uribe Email: send email Telefono: -5576257 Fax: -5576257	CH (YVERDON-LES-BAINS)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The project PharMEA is based on the technology platform of multi-electrode arrays, which have been widely used for electrophysiological experiments on neuronal and cardiac tissues. Some of the key advantages of MEA technology include ease of use, non-invasive measurements and simultaneous multi-site recording & stimulation capability. Despite these key advantages, MEA technology utilization has remained largely confined in academic research institutions, primarily due to the low throughput of currently available MEA-based tools. The PharMEA project addresses these shortcomings by developing novel MEA tools and applications that will significantly increase throughput of MEA experiments, facilitate MEA experiments on various culture models, as well as associated applications tailored for the drug discovery industry. Specifically, the new MEA tools will increase the number of channels or measurement sites for simultaneous recording and stimulation from about 120 channels today to 1024 channels, along with the corresponding intelligent data handling and processing strategies. Furthermore, the PharMEA project will develop and automate biological assay protocols that are common in ion-channel based drug discovery activities, as we this will add significant value to and bring out the benefit of the proposed tools. Altogether, the results of this project will accelerate the uptake of MEA tools in the drug discovery industry, thereby significantly increasing the market opportunity and competitive edge of the various sponsoring SMEs in the lucrative drug discovery industry.'